Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease (AD) is the leading cause of degenerative dementia in the aging population. Patients with AD have alterations in cerebral hemodynamic function including reduced cerebral blood flow (CBF) and cerebral metabolic rate. Therefore, improved cerebrovascular function may be an attractive goal for pharmaceutical intervention in AD. OBJECTIVE: We wished to observe the acute effects of sildenafil on cerebrovascular function and brain metabolism in patients with AD. METHODS: We used several novel non-invasive MRI techniques to investigate the alterations of CBF, cerebral metabolic rate of oxygen (CMRO2), and cerebrovascular reactivity (CVR) after a single dose of sildenafil administration in order to assess its physiological effects in patients with AD. CBF, CMRO2, and CVR measurements using MRI were performed before and one hour after the oral administration of 50 mg sildenafil. Baseline Montreal Cognitive Assessment score was also obtained. RESULTS: Complete CBF and CMRO2 data were obtained in twelve patients. Complete CVR data were obtained in eight patients. Global CBF and CMRO2 significantly increased (p = 0.03, p = 0.05, respectively) following sildenafil administration. Voxel-wise analyses of CBF maps showed that increased CBF was most pronounced in the bilateral medial temporal lobes. CVR significantly decreased after administration of sildenafil. CONCLUSION: Our data suggest that a single dose of sildenafil improves cerebral hemodynamic function and increases cerebral oxygen metabolism in patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237 · cited 1×
“Epidemiologic studies have shown that AD and vascular disease share many risk factors including hypertension, diabetes, hyperhomocysteinemia, obesity, and hyperlipidemia [5–7].”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Kety, S. S., & Schmidt, C. F. (1948) · Journal of Clinical Investigation · doi:10.1172/jci101995 · Cited by 1,827 · cited 1×
“:3) mol O 2 /min/100 g brain tissue) was quantified based on Fick principle of arteriovenous difference in oxygen content [37]: CMRO 2 = CBF × (Ya-Yv) × Ch, where CBF is total cerebral blood flow and is already measured with phase-contrast as described above; Ya is the arterial blood oxygenation, and…”
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
A Brief History of Long-Term Potentiation
Nicoll, R. A. (2017) · Neuron · doi:10.1016/j.neuron.2016.12.015 · Cited by 841
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 1×
“Hypoxiainducible factor-1α (HIF-1α) leads to increased β-secretase 1 (BACE-1) transcription, which occurs through HIF-1α binding to the hypoxia-responsive element in the promotor region of the BACE-1 gene [53].”
Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats
Zhang, R., Wang, Y., Zhang, L., Zhang, Z., Tsang, W., Lu, M., Zhang, L., & Chopp, M. (2002) · Stroke · doi:10.1161/01.str.0000034399.95249.59 · Cited by 383
Arancio, O., Kiebler, M., Lee, C. J., Lev-Ram, V., Tsien, R. Y., Kandel, E. R., & Hawkins, R. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81797-3 · Cited by 357
Expression of NMDA receptor-dependent LTP in the hippocampus: bridging the divide
Bliss, T. V., & Collingridge, G. L. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-5 · Cited by 305 · cited 1×
“some forms utilizing NO signaling and others not [69, 71, 72].”
Effect of infarcts on dementia in the Baltimore longitudinal study of aging
Troncoso, J. C., Zonderman, A. B., Resnick, S. M., Crain, B., Pletnikova, O., & O'Brien, R. J. (2008) · Annals of Neurology · doi:10.1002/ana.21413 · Cited by 219
Zhang, L., Zhang, R. L., Wang, Y., Zhang, C., Zhang, Z. G., Meng, H., & Chopp, M. (2005) · Stroke · doi:10.1161/01.str.0000158923.19956.73 · Cited by 198
Han, B. H., Zhou, M.-L., Abousaleh, F., Brendza, R. P., Dietrich, H. H., Koenigsknecht-Talboo, J., Cirrito, J. R., Milner, E., Holtzman, D. M., & Zipfel, G. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4686-08.2008 · Cited by 138 · cited 1×
“Furthermore, there is evidence from transgenic mouse models of AD that amyloid-β interferes with cerebrovascular responses to vasodilatory stimuli [59, 60].”
Zhang, R. L., Zhang, Z., Zhang, L., Wang, Y., Zhang, C., & Chopp, M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20813 · Cited by 138 · cited 1×
“Several studies have shown improved functional outcomes in rat models of stroke [13–16], even when treatment with a PDE5 inhibitor was delayed by as much as 7 days [15].”
Ding, G., Jiang, Q., Li, L., Zhang, L., Zhang, Z. G., Ledbetter, K. A., Panda, S., Davarani, S. P., Athiraman, H., Li, Q., et al. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.33 · Cited by 138 · cited 1×
“[46] also reported that after 7 days of sildenafil treatment, elevated CBF was observed in rats with stroke.”
Colton, C. A., Vitek, M. P., Wink, D. A., Xu, Q., Cantillana, V., Previti, M. L., Van Nostrand, W. E., Weinberg, J. B., & Dawson, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601075103 · Cited by 128
Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler
Claassen, J. A. H. R., Diaz-Arrastia, R., Martin-Cook, K., Levine, B. D., & Zhang, R. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1079 · Cited by 95 · cited 2×
“One study [1] revealed that compared to healthy controls, CBF and the variability of cerebral arterial velocity in AD patients is reduced while cerebrovascular resistance is increased.”
Self-citationWebster, N. J., Green, K. N., Peers, C., & Vaughan, P. F. T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01236.x · Cited by 56
Cited by
Fang, J., Zhang, P., Zhou, Y., Chiang, C.-W., Tan, J., Hou, Y., Stauffer, S., Li, L., Pieper, A. A., Cummings, J., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00138-z · Cited by 206
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Metadata
- Authors
- Sheng, M., Lu, H., Liu, P., Li, Y., Ravi, H., Peng, S.-L., Diaz-Arrastia, R., Devous, M. D., & Womack, K. B.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-11-07
- Volume
- 60
- Issue
- 4
- Pages
- 1351-1364
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2762770632
- Cited by
- 75
- References
- 18
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.